Central Nervous System
AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention
At the American Academy of Neurology (AAN) 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive…
Bayer and AskBio report data from Parkinson’s disease therapy trial
Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have reported data from an 18-month Phase Ib clinical trial of a gene…
Actinogen treats first subject in Alzheimer’s disease therapy trial
Australian biotechnology company Actinogen Medical has treated the first subject in the XanaMIA Phase IIb clinical trial of Xanamem in…
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
AviadoBio treats first subject in trial of FTD-GRN therapy
UK-based biotechnology company AviadoBio has administered its investigational gene therapy, AVB-101, to the first subject in the Phase I/II ASPIRE-FTD…
Teva’s Ajovy hits endpoint in Chinese Phase III trial for migraine prevention
Teva Pharmaceuticals has unveiled positive data from a Phase III study evaluating Ajovy (fremanezumab) for the prevention of migraines in…
SpineX eyes FDA submission as neurogenic bladder trial hits milestone
SpineX has closed recruitment for a clinical study investigating its neuromodulation device to treat urinary incontinence. Data from the trial,…
FDA gives nod to BrainStorm for ALS trial after Phase III flop
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
BMS’ schizophrenia treatment reduces symptoms in Phase III trial
Bristol Myers Squibb (BMS) has announced new interim data from the Phase III EMERGENT-4 open-label extension trial where KarXT (xanomeline-trospium)…
myTomorrows partners with UK brainstrust to improve access to clinical trials
Netherlands-based myTomorrows and UK-based charity brainstrust have partnered to improve patient and clinician access and awareness of clinical trials for…
